News for Palatin Technologies Stock (PTN)

Palatin Receives $4.7 Million of Non-Dilutive Funding

PRNewsWire • 01/18/23

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

PRNewsWire • 01/10/23

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results

PRNewsWire • 01/05/23

Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research • 11/14/22

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

PRNewsWire • 11/14/22

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

PRNewsWire • 11/09/22

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting

PRNewsWire • 10/24/22

First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial

PRNewsWire • 10/20/22

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results

PRNewsWire • 10/13/22

Palatin: Inhibitor Drug With Potential In Several Autoimmune Disorders

Seeking Alpha • 10/05/22

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

PRNewsWire • 09/29/22

Palatin to Participate in Ladenburg Thalmann Healthcare Conference

PRNewsWire • 09/29/22

Palatin Technologies, Inc. (PTN) Q4 2022 Earnings Call Transcript

Seeking Alpha • 09/23/22

Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

PRNewsWire • 09/22/22

Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022

PRNewsWire • 09/19/22

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

PRNewsWire • 09/08/22

3 Penny Stocks That Could 10X by 2023

InvestorPlace • 09/02/22

Palatin Technologies (PTN) Stock: 1-For-25 Reverse Split Goes Into Effect

Pulse2 • 08/31/22

Palatin Announces Intent to Effect Reverse Stock Split

PRNewsWire • 08/19/22

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

PRNewsWire • 08/16/22

Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

PRNewsWire • 07/26/22

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2022 Results - Earnings Call Transcript

Seeking Alpha • 05/17/22

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research • 05/17/22

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

PRNewsWire • 05/17/22

Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

PRNewsWire • 05/12/22